Abstract
Poly(lactic-co-glycolic acid) (PLGA)-poly ethylene glycol (PEG) based amphiphilic branched copolymer nanoparticles (NPs) have been developed for controlled release of tuberculosis (TB) drugs which include rifampicin (RIF), isoniazid (INH) and pyrazinamide (PYZ). The drug loading efficiency and the percentage drug content of polymer NPs increase by increasing the amount of PEG content in polymer NPs. The branched PLGA-PEG based copolymer NPs exhibit initial burst release followed by sustained release of RIF for 840 h, INH for 72 h, and PYZ for 720 h. The branched citrate-PEG-PLGA copolymer NPs can act as potential drug carriers when compared to their linear analogues.
| Original language | English |
|---|---|
| Pages (from-to) | 181-188 |
| Number of pages | 8 |
| Journal | Journal of Industrial and Engineering Chemistry |
| Volume | 77 |
| DOIs | |
| State | Published - 25 Sep 2019 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Citrate-PEG-PLGA branched copolymer
- In vitro drug release
- Isoniazid
- Polymer nanoparticles
- Pyrazinamide
- Rifampicin
Fingerprint
Dive into the research topics of 'In vitro controlled release of tuberculosis drugs by amphiphilic branched copolymer nanoparticles'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver